Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of capecitabine + temozolomide versus 5-fluorouracil + streptozocin, with or without bevacizumab, in well-differentiated pancreatic neuroendocrine tumors
2017-000741-46Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Oct 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, temozolomide, bevacizumab, fluorouracil, streptozocin and 1 more in islet cell tumor (4 arms), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival. Started Oct 2017; status: active.
02
Drugs
capecitabinetemozolomidebevacizumabfluorouracilstreptozocin
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2017-000741-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000741-46.